Diprophylline
Chemical compound
- R03DA01 (WHO)
- US: ℞-only
- 7-(2,3-Dihydroxypropyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione
- 479-18-5
Y
- 3182
- 7070
- DB00651 Y
- 3070 Y
- 263T0E9RR9
- D00691 Y
- CHEBI:4728 Y
- ChEMBL1752 Y
- DTXSID6022975
- Interactive image
- O=C2N(c1ncn(c1C(=O)N2C)CC(O)CO)C
InChI
- InChI=1S/C10H14N4O4/c1-12-8-7(9(17)13(2)10(12)18)14(5-11-8)3-6(16)4-15/h5-6,15-16H,3-4H2,1-2H3Y
- Key:KSCFJBIXMNOVSH-UHFFFAOYSA-NY
Diprophylline (INN)[1] or dyphylline (USAN) (trade names Dilor, Lufyllin) is a xanthine derivative with bronchodilator and vasodilator effects. It is used in the treatment of respiratory disorders like asthma, cardiac dyspnea, and bronchitis. It acts as an adenosine receptor antagonist and phosphodiesterase inhibitor.[2][3]
See also
References
- ^ "International Non-Proprietary Names. Recommended International Non-Proprietary Names (Rec. I.N.N.): List 1" (PDF). World Health Organization. 1955. p. 188.
- ^ Schwabe U, Ukena D, Lohse MJ (September 1985). "Xanthine derivatives as antagonists at A1 and A2 adenosine receptors". Naunyn-Schmiedeberg's Archives of Pharmacology. 330 (3): 212–21. doi:10.1007/bf00572436. PMID 2997628. S2CID 12190457.
- ^ Iancu L, Shneur A, Cohen H (1979). "Trials with xanthine derivatives in systemic treatment of psoriasis". Dermatologica. 159 (1): 55–61. doi:10.1159/000250562. PMID 225216.
- v
- t
- e
| Short-acting β2 agonists | |
|---|---|
| Long-acting β2 agonists |
|
| Ultra-long-acting β2 agonists | |
| Other |
muscarinic antagonist
| Leukotriene antagonists | |
|---|---|
| Arachidonate 5-lipoxygenase inhibitors | |
| Thromboxane receptor antagonists | |
| Non-xanthine PDE4 inhibitors |
- Aclidinium bromide/formoterol
- Beclometasone/formoterol
- Beclometasone/formoterol/glycopyrronium bromide
- Budesonide/formoterol
- Budesonide/glycopyrronium bromide/formoterol
- Fluticasone furoate/umeclidinium bromide/vilanterol
- Fluticasone furoate/vilanterol
- Fluticasone propionate/salmeterol
- Glycopyrronium bromide/formoterol
- Indacaterol/glycopyrronium bromide
- Indacaterol/glycopyrronium bromide/mometasone
- Indacaterol/mometasone
- Ipratropium bromide/salbutamol
- Mometasone/formoterol
- Salbutamol (albuterol)/budesonide
- Umeclidinium bromide/vilanterol
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
